Press release
Thyroid Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies
Thyroid Cancer Pipeline
Key Takeaways from the Thyroid Cancer Pipeline Report
• DelveInsight's Thyroid Cancer Pipeline analysis depicts a robust space with 40+ active players working to develop 40+ pipeline treatment therapies.
• The leading companies working in the Thyroid Cancer Market include Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
• Promising Thyroid Cancer Pipeline Therapies in the various stages of development include Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
• December 2023: Novartis Pharmaceuticals announced a study of Phase 3 clinical trials for Trametinib and Dabrafenib. This is a global, multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid cancer who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy.
• November 2023: Affylmmune Therapeutics Inc. announced a study of Phase 1 clinical trials for AIC100 CAR T Cells. The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.
• In July 2023, Eisai Limited announced a study of phase 1 & 2 clinical trials for Lenvatinib, Ifosfamide, and Etoposide. This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid malignancies including differentiated thyroid carcinoma (single agent lenvatinib) and osteosarcoma (single agent and combination lenvatinib).
• On January 2023, Famewave Ltd announced a study of phase 1 & 2 clinical trials for Nivolumab and Nal-IRI/5-FU/LV - Expansion. This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C & D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.
Request a sample and discover the recent advances in Thyroid Cancer Treatment Drugs @ Thyroid Cancer Pipeline Outlook Report- https://www.delveinsight.com/report-store/thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Thyroid Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Thyroid Cancer Overview
Thyroid cancer starts in the cells that make up your thyroid gland. The thyroid gland makes hormones that help control many processes in your body. Thyroid cancer is relatively common enough so that all of us will know somebody with thyroid cancer. There are more than 50,000 new cases of thyroid cancer each year in the United States. Women are more likely to develop thyroid cancer at a ratio of three to one.
Find out more about Thyroid Cancer Therapeutics Assessment @ Thyroid Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Thyroid Cancer Emerging Drugs Profile
• Donafenib: Suzhou Zelgen Biopharmaceuticals
• Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical
• Nivolumab: Bristol-Myers Squibb
• RX208: Suzhou NeuPharma
• AIC100: AffyImmune Therapeutics
Thyroid Cancer Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the Thyroid Cancer therapies. The Thyroid Cancer companies which have their Thyroid Cancer drug candidates in the most advanced stage, i.e. phase III include, Suzhou Zelgen Biopharmaceuticals.
Request a sample and discover the recent advances in Thyroid Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Thyroid Cancer Segmentation- https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Thyroid Cancer Drugs and Companies
• Rosiglitazone: Exelixis
• Lenvatinib: Eisai Limited
• Ifosfamide: Merck Sharp & Dohme LLC
Thyroid Cancer Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Thyroid Cancer Therapeutics Market include-
Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
Dive deep into rich insights for drugs for Thyroid Cancer Pipeline, click here @ Thyroid Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Thyroid Cancer Pipeline Report
• Coverage- Global
• Thyroid Cancer Companies- Suzhou Zelgen Biopharmaceuticals, Jiangsu Chia-Tai Tianqing Pharmaceutical, Takeda, Bristol-Myers Squibb, Genentech, AffyImmune Therapeutics Inc., Taizhou Hanzhong biomedical co. Ltd, NantCell Inc., Bayer, Merck Sharp & Dohme Corp., Pfizer, MedImmune LLC, Eisai Inc., cCAM Biotherapeutics, Purple Biotech Ltd., Turning Point Therapeutics, Inc., Hoffmann-La Roche, Bicara Therapeutics, Novartis, GlobeImmune, GE Healthcare, IBC Pharmaceuticals, Debiopharm, Blueprint Medicines, Ono Pharmaceutical, Array BioPharma, Celldex Therapeutics Inc., VBL Therapeutics, Biovista, and others.
• Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Thyroid Cancer Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Thyroid Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Thyroid Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Donafenib: Suzhou Zelgen Biopharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Nivolumab: Bristol-Myers Squibb
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. AIC100: Affyimmune Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Thyroid Cancer Key Companies
21. Thyroid Cancer Key Products
22. Thyroid Cancer- Unmet Needs
23. Thyroid Cancer- Market Drivers and Barriers
24. Thyroid Cancer- Future Perspectives and Conclusion
25. Thyroid Cancer Analyst Views
26. Thyroid Cancer Key Companies
27. Appendix
List of Important Published Links
http://proweb.vforums.co.uk/board/Res/topic/6864/action/view_topic/vital-sign-monitoring-devices-market
http://astarsuzuki.vforums.co.uk/general/9070/vital-sign-monitoring-devices-market
http://weareone.vforums.co.uk/general/7485/vital-sign-monitoring-devices-market
http://baigasciedil.vforums.co.uk/general/9817/vital-sign-monitoring-devices-market#9817
http://taresources.vforums.co.uk/board/general/topic/10493/action/view_topic/vital-sign-monitoring-devices-market
http://clapecasna.vforums.co.uk/general/6561/vital-sign-monitoring-devices-market
http://feiwabpagym.vforums.co.uk/general/5813/vital-sign-monitoring-devices-market
http://whatwentwrong.vforums.co.uk/general/6172/vital-sign-monitoring-devices-market-dynamics
http://freuniontest.vforums.co.uk/general/4986/vital-sign-monitoring-devices-market-segmentation
http://testforum.vforums.co.uk/board/general/topic/5292/action/view_topic/vital-sign-monitoring-devices-market-size
https://kktix.com/user/5068280
https://network-373.mn.co/posts/48353213
https://body-imagine.mn.co/posts/48353364
https://pimpmyairgun.mn.co/posts/48353478
https://gtribe.mn.co/posts/advancements-and-opportunities-in-the-vulvar-cancer-market
https://communenour.mn.co/posts/emerging-trends-and-market-dynamics-in-vulvar-cancer-treatment
https://synkretic.mn.co/posts/understanding-the-vulvar-cancer-market-trends-challenges-and-innovations
https://jlfa2020.mn.co/members/16644457
https://dbook.mn.co/posts/48401881
https://lxgonline.mn.co/posts/navigating-the-landscape-of-hypertriglyceridemia-market-current-trends-and-future-prospects
https://www.penname.me/@dennydones99
https://community.fyers.in/member/7Yldtdsvui
https://spurstartup.mn.co/posts/48406045
https://pressurecooker.mn.co/posts/48406225
https://regenerative-future.mn.co/posts/navigating-the-hypertriglyceridemia-market-innovations-and-challenges
https://commiss.io/dennydones
https://www.pledgeme.co.nz/profiles/221820/
https://brave-comfort.mn.co/posts/48409148
https://gamebook.mn.co/posts/navigating-the-landscape-of-the-hypertriglyceridemia-market
https://biomolecula.ru/authors/25303
https://discuss.machform.com/u/dennydones9191
https://dagshub.com/dennydones9191
https://careerkarma.com/profile/clr7d7z0c04v2lf3k5lrx9vyr/
https://gotech.mn.co/posts/48477911
https://landmarknew.mn.co/posts/48477947
https://infiniteabundance.mn.co/posts/48478016
https://wellbeingmatters.mn.co/posts/48478424
https://vrjam.mn.co/posts/48478544
https://decidim.santcugat.cat/profiles/dennydones9/activity
https://haveagood.holiday/users/336105
https://participa.rubi.cat/profiles/dennydones9191/activity
https://forum.callofwar.com/index.php?user/60304-dennydones9191/#about
https://connectgalaxy.com/post/146081_syphilis-a-sexually-transmitted-bacterial-infection-caused-by-treponema-pallidum.html
https://www.thebostoncalendar.com/user/74833
https://wrongplanet.net/author/dennydones9999/
https://bookmark.hiauthors.com/story/syphilis-market
https://www.openhumans.org/member/anniethomas/
https://cynochat.com/read-blog/160375
https://hitrecord.org/users/dennydones9999/records
https://biiut.com/read-blog/918
https://nimmansocial.com/story5840956/syphilis-market
https://bookmarkbirth.com/story15878475/syphilis-market
https://quantummemoir.mn.co/members/21285995
https://rightbusinesspath.mn.co/posts/48636294
https://tennispassion.mn.co/posts/48636354
https://king-business.mn.co/posts/48636411
https://forums.mbclub.co.uk/members/dennydones99.180319/#about
https://www.creativelive.com/student/dennydones1?via=accounts-freeform_2
https://tl.net/forum/profile.php?user=dennydones99
https://minne.com/@dennydones99/profile
https://network-79379.mn.co/members/20103624
https://ylimun.mn.co/members/20103614
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/stem-cell-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Thyroid Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies here
News-ID: 3351570 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Thyroid
Rising Incidences of Thyroid Disorders Fuel Growth In The Thyroid Function Test …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Thyroid Function Test Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for thyroid function tests has witnessed substantial growth in the past few years. The market is projected to expand from $1.7 billion in 2024 to $1.81 billion in 2025, with an…
Rising Incidences of Thyroid Disorders Fuel Growth In The Thyroid Function Test …
The Thyroid Function Test Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Thyroid Function Test Market Size During the Forecast Period?
The thyroid function test market has grown significantly in recent years. It is expected to grow from $1.7 billion in 2024…
Thyroid Function Test Market Report 2024 - Thyroid Function Test Market Growth A …
"The Business Research Company recently released a comprehensive report on the Global Thyroid Function Test Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
Thyroid Ablation Devices Market
Alarming rise in prevalence of thyroid cancer, advancements in thyroid ablation system, rise in government & private funds for development of healthcare sectors, and increase in number of thyroid nodule cases are expected to notably contribute toward the growth of the global thyroid ablation devices market during the forecast period.
Rise in prevalence of thyroid cancer and thyroid nodules, demand for minimally invasive procedures, and technological advancements in ablation devices drive…
Thyroid Gland Disorders Treatment Market Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of…
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view…
